New immune cell therapy tested for Tough-to-Treat cancers
NCT ID NCT07487597
Summary
This early-stage trial is testing a new type of cell therapy for people with advanced solid tumors that have a specific protein called ALPP. The therapy involves collecting a patient's own immune cells, modifying them in a lab to better target the cancer, and then infusing them back. The main goals are to find a safe dose and see if the treatment shows early signs of helping control the cancer in patients who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Jinling Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.